Guidance for Healthcare Professionals

Why Early and Proactive Treatment Matters

Nausea and vomiting in pregnancy (NVP) affects up to 80% of pregnant women, with hyperemesis gravidarum (HG) representing the severe end of the spectrum at 1-3% of pregnancies. Despite its prevalence, NVP remains one of the most under-treated conditions in obstetric care. There is strong evidence that early intervention reduces symptom severity, prevents progression to HG, decreases emergency department attendances, and reduces hospital admissions.

A proactive treatment approach, initiated at the first signs of worsening symptoms, is associated with:

• Shorter overall duration of illness
• Reduced severity of nausea and vomiting at peak
• Lower rates of hospital admission for IV fluid rehydration
• Reduced psychological morbidity, including lower rates of antenatal depression and anxiety
• Fewer pregnancy terminations for intractable symptoms
• Improved maternal quality of life and ability to maintain employment

The "wait and see" approach has been shown to lead to worse outcomes. Women who present early and are offered antiemetics promptly have significantly better symptom control compared with those whose treatment is delayed. A Cochrane review of interventions for NVP confirms that pharmacological treatments are effective and should not be withheld due to unfounded safety concerns.

RCOG Green-top Guideline: Management of NVP and HG

The Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline No. 69 provides the definitive UK guidance on the management of nausea and vomiting of pregnancy and hyperemesis gravidarum. Key recommendations include:

• Diagnosis: HG is a diagnosis of exclusion. Other causes of vomiting (UTI, thyroid disease, molar pregnancy, gastrointestinal conditions) should be considered, particularly if presentation is atypical or onset is after 12 weeks.
• Assessment: Use a validated scoring tool such as the Pregnancy-Unique Quantification of Emesis (PUQE) score to objectively assess severity and guide treatment decisions.
• Treatment should be offered early: Antiemetics are safe and effective. Treatment should be stepped up as needed rather than waiting for symptoms to become severe.
• Ambulatory care: Day-case IV fluid rehydration is preferred over inpatient admission where clinically appropriate and local services permit.
• Thiamine supplementation: Should be considered for all women with prolonged vomiting to prevent Wernicke's encephalopathy.
• Psychological support: The psychological impact of NVP and HG is significant and should be actively assessed and addressed.
• Thromboprophylaxis: Consider VTE risk assessment for all women admitted with HG, as dehydration and immobility increase the risk of thromboembolism.
• Subsequent pregnancies: Women with a history of HG should be counselled about the recurrence risk (approximately 75-80%) and offered a pre-pregnancy or early-pregnancy management plan.

Assessment: The PUQE Score

The Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score is a validated tool for objectively quantifying the severity of NVP. It should be used at initial assessment and to monitor treatment response. The score comprises three questions, each rated from 1 to 5, covering the preceding 24 hours:

Component	Score 1	Score 2	Score 3	Score 4	Score 5
Hours of nausea per day	None	1 hour or less	2-3 hours	4-6 hours	More than 6 hours
Number of vomiting episodes per day	None	1-2	3-4	5-6	7 or more
Number of retching episodes per day	None	1-2	3-4	5-6	7 or more

Interpreting the PUQE Score

Total Score	Severity	Recommended Action
3-6	Mild	Reassurance, dietary advice, consider antiemetic if affecting quality of life. Review in 1-2 weeks.
7-12	Moderate	Prescribe first-line antiemetic. Consider combination therapy. Review within 48-72 hours. Assess hydration.
13-15	Severe	Urgent assessment. Consider admission or ambulatory IV fluids. Combination antiemetics. Check bloods including electrolytes and thyroid function.

Clinical Assessment Checklist

Every woman presenting with significant NVP or suspected HG should undergo a thorough clinical assessment. The following checklist covers the essential parameters:

History

• Duration and pattern of nausea and vomiting (onset, timing, triggers)
• Oral intake assessment: ability to retain fluids and solids
• PUQE score (document in notes)
• Weight change: pre-pregnancy weight and current weight (weight loss of ≥5% is clinically significant; ≥10% indicates severe disease)
• Urinary output: frequency, colour, and volume
• Medications tried and response to treatment
• Functional impact: ability to work, care for self/children, leave the house
• Psychological wellbeing: screen for depression, anxiety, suicidal ideation
• Previous obstetric history: NVP/HG in prior pregnancies and what helped
• Exclude red flags: abdominal pain, fever, haematemesis, onset after 12 weeks

Examination

• Dehydration signs: dry mucous membranes, reduced skin turgor, tachycardia, postural hypotension, sunken eyes
• Abdominal examination: tenderness, distension (exclude surgical causes)
• Weight and BMI: compare to booking weight
• Observations: heart rate, blood pressure (lying and standing), temperature

Investigations

Investigation	Purpose	Key Findings
Urine dipstick (ketones)	Assess starvation and dehydration	Ketonuria (≥2+) indicates significant starvation. Note: absence of ketones does not exclude dehydration.
Urea and electrolytes	Assess renal function and electrolyte imbalance	Hypokalaemia, hyponatraemia, raised urea. Severe cases may show hypochloraemic metabolic alkalosis.
Thyroid function tests	Exclude hyperthyroidism; assess gestational thyrotoxicosis	Transient gestational thyrotoxicosis (suppressed TSH, mildly raised free T4) is common in HG and usually resolves without antithyroid treatment. Distinguish from Graves' disease.
FBC	Baseline; assess haemoconcentration	Raised haematocrit suggests dehydration.
LFTs	Hepatic involvement in severe HG	Mildly raised transaminases seen in up to 50% of women admitted with HG. Usually resolves with rehydration.
MSU	Exclude urinary tract infection	UTI can mimic or exacerbate NVP.
Ultrasound scan	Confirm viable pregnancy, exclude multiple pregnancy and molar pregnancy	Multiple pregnancies and molar pregnancies are associated with more severe NVP/HG.

First-Line Treatment Algorithm: A Stepped Approach

Treatment should follow a stepwise approach, escalating promptly when a given step fails to adequately control symptoms. Do not persist with an ineffective treatment for more than 24-48 hours before stepping up. The goal is not merely to reduce vomiting but to enable the woman to eat, drink, function, and maintain her wellbeing.

Step 1: Mild NVP (PUQE 3-6)

• Reassurance and dietary advice (small frequent meals, bland foods, avoid triggers)
• Ginger supplements (250mg four times daily) or vitamin B6 (pyridoxine 10-25mg three times daily)
• Acupressure wristbands (P6 point)
• If symptoms are affecting quality of life, proceed to Step 2 without delay

Step 2: Moderate NVP (PUQE 7-12) or Mild NVP Not Responding

• First-line antiemetic monotherapy:
  • Cyclizine 50mg up to three times daily (oral, IM, or IV)
  • Promethazine 12.5-25mg up to four times daily (oral, IM)
  • Prochlorperazine 5-10mg up to three times daily (oral, buccal, IM)
• Review within 24-48 hours. If no improvement, switch antiemetic class or add second agent.

Step 3: Moderate-Severe NVP or Inadequate Response to Step 2

• Combination antiemetic therapy (use drugs from different classes):
  • Cyclizine + Metoclopramide 10mg up to three times daily (limit to 5 days)
  • Promethazine + Prochlorperazine
• Add ondansetron 4-8mg up to three times daily (oral or IV)
• Domperidone 10mg up to three times daily as an alternative prokinetic
• Assess hydration status. Consider ambulatory IV fluids if oral intake is poor.

Step 4: Severe NVP / Hyperemesis Gravidarum (PUQE 13-15)

• Admit to hospital or commence ambulatory IV fluid regimen
• Combination antiemetics, including ondansetron, via IV route if oral route not tolerated
• IV thiamine before or alongside IV dextrose-containing fluids
• Check and correct electrolytes
• VTE risk assessment and thromboprophylaxis

Step 5: Refractory HG

• Corticosteroids: hydrocortisone 100mg IV twice daily, converting to prednisolone 40-50mg oral daily, tapering over 2-3 weeks. Avoid before 10 weeks' gestation if possible (possible association with cleft palate at very high doses in first trimester).
• Consider nasogastric or nasojejunal tube feeding in severe prolonged cases
• Total parenteral nutrition (TPN) is a last resort with significant complication risks
• Multidisciplinary input: obstetrics, gastroenterology, dietetics, psychology/psychiatry

Antiemetic Medication Safety in Pregnancy

The following table summarises the antiemetic medications used in the management of NVP and HG, including dosing, safety evidence, and breastfeeding compatibility. All listed medications are considered acceptable for use in pregnancy based on current evidence and RCOG/NICE guidance.

Drug	Class	Dose & Route	Pregnancy Safety Evidence	Breastfeeding
Cyclizine	Antihistamine (H1 antagonist)	50mg PO/IM/IV up to TDS	Extensive use over decades. No increase in congenital malformation rate in large cohort studies. Reassuring safety profile.	Compatible. Small amounts in breast milk. No reported adverse effects in breastfed infants.
Promethazine	Antihistamine (H1 antagonist) / phenothiazine	12.5-25mg PO/IM up to QDS	Long safety record. Included in multiple meta-analyses showing no increased teratogenic risk. More sedating than cyclizine.	Compatible. Use with caution due to sedative properties; observe infant for drowsiness.
Prochlorperazine	Phenothiazine (dopamine antagonist)	5-10mg PO/IM TDS or 3-6mg buccal BD	Widely used in pregnancy. Large epidemiological studies show no significant increase in malformation risk. Rare extrapyramidal side effects.	Compatible. Monitor infant for drowsiness or irritability.
Metoclopramide	Dopamine antagonist / prokinetic	10mg PO/IM/IV up to TDS. Limit to 5 days continuously (MHRA).	Large Israeli cohort study (>80,000 exposures) showed no increased malformation risk. MHRA restriction to 5 days due to extrapyramidal/tardive dyskinesia risk (non-pregnancy-specific).	Compatible. Present in breast milk in small quantities. May increase prolactin/milk supply.
Ondansetron	5-HT3 receptor antagonist	4-8mg PO/IV up to TDS	Extensive data. Possible small increase in cleft palate risk with first trimester use (absolute risk increase ~3 per 10,000, from 11 to 14 per 10,000). No increase in cardiac malformations. See detailed section below. Benefits often outweigh risks in moderate-severe NVP/HG.	Limited data. Likely compatible based on pharmacological properties. Use clinical judgement.
Domperidone	Dopamine antagonist / prokinetic	10mg PO up to TDS	Less human data than other agents but no signal for teratogenicity. Does not cross the blood-brain barrier readily (fewer CNS side effects). MHRA cardiac risk warnings apply (non-pregnancy-specific).	Compatible. Commonly used to promote lactation. Very small amounts in breast milk.
Corticosteroids	Glucocorticoid	Hydrocortisone 100mg IV BD, then prednisolone 40-50mg PO OD, tapering over 2-3 weeks	Reserved for refractory HG. Possible small increased risk of cleft palate with first trimester use at high doses (similar magnitude to ondansetron). Avoid before 10 weeks if possible. Risk of gestational diabetes, adrenal suppression with prolonged use.	Prednisolone compatible. Minimal transfer to breast milk at doses ≤40mg/day. Delay feeding by 4 hours after high doses if concerned.

IV Fluid Management Protocol

Intravenous fluid therapy is indicated when oral intake is insufficient to maintain hydration, when ketonuria is present (≥2+), or when clinical signs of dehydration are apparent. The following protocol aligns with RCOG recommendations:

Choice of Fluid

• Normal saline (0.9% NaCl): First-line choice. Replaces sodium and chloride losses from vomiting. Preferred over dextrose-containing solutions initially.
• Hartmann's solution (compound sodium lactate): An acceptable alternative with a more physiological electrolyte profile. Contains potassium (5mmol/L), so less additional potassium supplementation may be needed.
• Avoid dextrose-only solutions: Dextrose (5% or 10%) should not be used as the sole resuscitation fluid. It can precipitate Wernicke's encephalopathy in thiamine-depleted patients by increasing metabolic demand for thiamine. If dextrose is used, always give IV thiamine first.

Fluid Regimen

• Typical initial regimen: 1 litre of normal saline over 2-4 hours, followed by clinical reassessment
• Total daily requirement is usually 2-3 litres, adjusted according to clinical response, urine output, and ongoing losses
• Monitor fluid balance carefully; avoid fluid overload in women with cardiac or renal concerns

Potassium Replacement

• Check serum potassium before commencing IV fluids
• Hypokalaemia is common in prolonged vomiting and can cause cardiac arrhythmias, muscle weakness, and ileus
• If potassium is low, add 20-40mmol KCl per litre of saline (maximum rate 10mmol/hour via peripheral cannula)
• Recheck electrolytes within 24 hours and after each litre of potassium-supplemented fluid
• Severe hypokalaemia (<2.5mmol/L) requires cardiac monitoring and may need central venous access for concentrated replacement

Thiamine Supplementation with IV Fluids

• IV thiamine (Pabrinex) should be given before or alongside any dextrose-containing fluid
• Recommended dose: Pabrinex IV High Potency one pair of ampoules diluted in 100ml saline, infused over 30 minutes, once daily for 3-5 days
• Oral thiamine (25-50mg three times daily) should be continued on discharge for the duration of symptoms

Thiamine Deficiency and Wernicke's Encephalopathy

Wernicke's encephalopathy (WE) is an acute neurological emergency caused by thiamine (vitamin B1) deficiency. It is an under-recognised complication of hyperemesis gravidarum that carries devastating consequences if missed. The classic triad of confusion, ataxia, and ophthalmoplegia is present in only a minority of cases; most present with incomplete features.

Risk Factors for WE in HG

• Vomiting lasting more than 3 weeks
• Significant weight loss (≥5% of pre-pregnancy weight)
• Prolonged inability to tolerate oral intake
• Administration of IV dextrose without thiamine supplementation
• Parenteral nutrition without adequate thiamine

Clinical Features (may be subtle or incomplete)

• Confusion: disorientation, apathy, poor concentration, confabulation
• Oculomotor dysfunction: nystagmus, lateral rectus palsy, conjugate gaze palsy
• Ataxia: unsteady gait, wide-based stance, inability to stand unaided
• Peripheral neuropathy, hypothermia, tachycardia

Thiamine Supplementation Protocol

Scenario	Thiamine Regimen
Prophylaxis: Outpatient with prolonged vomiting	Oral thiamine 25-50mg TDS until symptoms resolve and diet normalises
Prophylaxis: Inpatient admission for HG	IV Pabrinex (1 pair ampoules in 100ml saline over 30 minutes) once daily for 3-5 days, then oral thiamine on discharge
Treatment: Suspected Wernicke's encephalopathy	IV Pabrinex (2 pairs of ampoules in 100ml saline over 30 minutes) three times daily for 3-5 days, then 1 pair daily until clinical improvement. Urgent neurology referral.

When to Admit to Hospital

Hospital admission should be considered when outpatient management has failed or when clinical parameters indicate a need for close monitoring and IV therapy. The following criteria should prompt admission or urgent ambulatory care:

Criterion	Threshold for Admission / Urgent Care
Inability to retain oral fluids	Unable to keep any fluids down for more than 12 hours
Ketonuria	≥2+ on urine dipstick
Weight loss	≥5% of pre-pregnancy body weight
Clinical dehydration	Tachycardia (>100bpm), postural hypotension, dry mucous membranes, reduced urine output
Electrolyte abnormality	Hypokalaemia (<3.5mmol/L), hyponatraemia (<130mmol/L), or other significant disturbance
Failed outpatient treatment	No improvement despite adequate trial of combination oral antiemetics (minimum 48 hours)
Co-morbidities	Pre-existing diabetes (risk of DKA), renal impairment, cardiac conditions
Concern about Wernicke's encephalopathy	Any neurological symptoms: confusion, visual disturbance, ataxia
Safeguarding / social concerns	Unable to care for self or dependants, unsafe home environment, no support
Psychological crisis	Suicidal ideation, expressed desire to terminate a wanted pregnancy solely due to symptoms

Ondansetron: The Evidence on Safety

Ondansetron is one of the most effective antiemetics available and has become a cornerstone of HG management. However, concerns about a possible association with orofacial clefts have led to uncertainty among some prescribers. It is important to understand the evidence in context:

What the Studies Show

• A large Danish cohort study (Pasternak et al., 2013, NEJM) found no overall increase in malformation rates with first-trimester ondansetron exposure.
• A subsequent larger study (Huybrechts et al., 2018, JAMA) involving over 88,000 ondansetron-exposed pregnancies found a small, statistically significant increase in cleft palate risk: from 11.1 per 10,000 unexposed pregnancies to approximately 14.0 per 10,000 exposed pregnancies.
• This represents an absolute risk increase of approximately 3 additional cases per 10,000 exposures, or a number needed to harm of approximately 3,300.
• No increase in cardiac malformations was found, contradicting earlier smaller studies.
• The EMA reviewed the data in 2019 and recommended that ondansetron should not be used in the first trimester. However, RCOG and many UK specialists continue to support its use when the clinical benefit outweighs this very small potential risk, particularly when other antiemetics have failed.

Putting the Risk in Context

• The background risk of cleft palate in the UK is approximately 1 in 700 births (14 per 10,000)
• The possible additional risk from ondansetron is approximately 3 per 10,000 (0.03%)
• For comparison, the background risk of any major congenital malformation is 2-3%
• Untreated severe HG carries risks including: Wernicke's encephalopathy, severe electrolyte disturbance, renal impairment, venous thromboembolism, psychological trauma, and pregnancy termination
• The absolute risk increase from ondansetron is substantially smaller than risks women commonly accept in pregnancy (e.g., driving a car, certain occupational exposures)

Psychological Impact: Screening for Depression and Anxiety

The psychological burden of NVP and HG is profound and frequently underestimated by healthcare providers. Research consistently demonstrates high rates of depression, anxiety, post-traumatic stress disorder (PTSD), and relationship breakdown among women with HG. Up to 49% of women with HG report depressive symptoms, and a significant proportion contemplate or proceed with termination of a wanted pregnancy purely because of symptom severity.

Screening Tools

Routine psychological screening should be integrated into the care of all women presenting with moderate-to-severe NVP or HG:

• PHQ-9 (Patient Health Questionnaire-9): A validated 9-item tool for screening and monitoring depression severity. Scores of 10 or above indicate at least moderate depression and warrant further assessment and intervention. Document the score and discuss the results with the patient.
• GAD-7 (Generalised Anxiety Disorder-7): A validated 7-item tool for screening generalised anxiety. Scores of 10 or above indicate at least moderate anxiety. Women with HG frequently score highly due to health anxiety, fear of eating/drinking, and anticipatory nausea.
• Direct questioning about suicidal ideation: Ask explicitly. Women with HG may feel too ashamed or concerned about being judged to volunteer this information. Questions such as "Have you had any thoughts of harming yourself or not wanting to be here?" should be asked in a non-judgemental manner.

Intervention

• Validate the patient's experience. Acknowledge that HG is a serious medical condition and that psychological distress is an expected and understandable response.
• Refer to perinatal mental health services where available
• Consider whether inadequate physical symptom control is driving the psychological symptoms (often, improving the NVP/HG treatment improves mental health significantly)
• SSRIs (e.g., sertraline) are safe in pregnancy and should be considered for women meeting criteria for moderate-to-severe depression
• Offer counselling or cognitive behavioural therapy (CBT) where accessible
• Reassess at every clinical contact. Psychological state can fluctuate with symptom severity.

Discussing Termination for Medical Reasons

Termination of a wanted pregnancy due to intractable HG is a devastating outcome that affects a significant minority of women with severe disease. Studies suggest that up to 10% of women with HG consider termination, and a smaller proportion proceed. In many cases, earlier or more aggressive treatment might have prevented this outcome.

Sensitive Guidance for Clinicians

• Listen without judgement. If a woman raises the subject of termination, she is telling you the severity of her suffering. This is a critical moment to review and escalate her treatment.
• Escalate treatment first. Before proceeding with termination, ensure that all available treatment options have been tried, including ondansetron, corticosteroids, and regular IV fluids. Refer to a clinician with specialist HG experience if possible.
• Acknowledge the validity of the decision. If all treatment options have been exhausted and the woman's quality of life remains incompatible with continuing the pregnancy, respect her autonomy. This is a legitimate medical decision.
• Provide non-directive counselling. Ensure the woman has access to counselling both before and after the decision. Guilt, grief, and PTSD are common sequelae.
• Document comprehensively. Record the clinical rationale, treatments tried, the patient's capacity and informed consent, and any counselling provided.
• Plan for the future. If termination proceeds, discuss the recurrence risk in future pregnancies and offer a pre-conception plan. Many women who terminated for HG go on to have successful subsequent pregnancies with proactive early treatment.

Planning Subsequent Pregnancies After HG

Women who have experienced HG in a previous pregnancy face an estimated 75-80% recurrence risk. This knowledge often causes significant anxiety when considering future pregnancies. A proactive pre-pregnancy plan can reduce the severity and duration of symptoms and provide psychological reassurance.

Pre-Conception Planning

• Pre-pregnancy consultation: Offer an appointment specifically to discuss a management plan before conception. This demonstrates that the woman's previous experience is taken seriously.
• Written management plan: Provide a letter or care plan that the woman can present to any healthcare professional she encounters in early pregnancy. This should outline her history and the agreed treatment approach, including specific medications and doses.
• Early antiemetic prescribing: Prescribe antiemetics to be started at the very first sign of nausea, even before a positive pregnancy test is confirmed if the woman is actively trying to conceive. Starting treatment before symptoms escalate is the single most effective strategy for reducing severity.
• Thiamine supplementation: Start oral thiamine (25-50mg daily) from conception or pre-conception.
• Psychological preparation: Consider referral to perinatal mental health services pre-conception, particularly if the previous HG experience caused PTSD or if the woman terminated a previous pregnancy due to HG.
• Practical preparation: Advise the woman to arrange support networks, childcare, and workplace accommodations in advance.

Discharge Planning and Community Follow-Up

Discharge from hospital should not mark the end of active management. Many women experience readmission because of inadequate community follow-up. A structured discharge plan reduces readmission rates and improves outcomes.

Discharge Checklist

• Tolerating oral fluids: The woman should be able to retain at least 500ml of oral fluids over 24 hours before discharge is considered.
• Oral antiemetics prescribed: Ensure a full supply of oral antiemetics is dispensed (not just a 3-day supply). Prescribe at least 2 weeks' supply and consider a combination regimen.
• Oral thiamine: Continue 25-50mg three times daily until symptoms resolve and oral intake normalises.
• Electrolytes normalised: Confirm that potassium and sodium are within normal range before discharge.
• Safety-netting advice: Provide clear written and verbal guidance on when to return (inability to retain fluids for more than 12 hours, dark urine, dizziness, confusion, reduced fetal movement).
• Follow-up arranged: GP review within 48-72 hours. Consider community midwife review within 1 week. If ambulatory IV service is available, arrange next appointment before discharge.
• Sick note provided: If the woman is employed, offer a fit note without her needing to request one. Many women with HG are too unwell to work and should not feel pressured to do so.
• VTE assessment: If the woman remains relatively immobile at home, consider extended thromboprophylaxis post-discharge.
• Mental health: Screen before discharge and document. Provide contact details for perinatal mental health services and the Pregnancy Sickness Support helpline.

Community Follow-Up

• GP or midwife review within 48-72 hours of discharge
• Reassess PUQE score, weight, hydration status, and mental health at every contact
• Adjust antiemetic regimen as needed; do not wait for the next scheduled appointment if symptoms worsen
• Maintain a low threshold for re-referral to secondary care or ambulatory IV service
• Continue to monitor weight regularly throughout pregnancy; women who have had HG are at increased risk of small-for-gestational-age babies

Resources for Healthcare Professionals

The following resources provide further detail on the evidence base and clinical management of NVP and HG:

• RCOG Green-top Guideline No. 69: The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. The definitive UK clinical guideline. Available from rcog.org.uk.
• NICE Clinical Knowledge Summary: Nausea/vomiting in pregnancy. Practical primary care guidance including when to refer. Available from cks.nice.org.uk.
• British National Formulary (BNF): Individual drug monographs with up-to-date prescribing information, including pregnancy and breastfeeding advice. Available from bnf.nice.org.uk.
• UK Teratology Information Service (UKTIS): Provides evidence-based information on drug exposures in pregnancy. Bumps (Best Use of Medicines in Pregnancy) patient information leaflets are available at medicinesinpregnancy.org.
• Cochrane Review: Interventions for nausea and vomiting in early pregnancy (Matthews et al.). Systematic review of the evidence for pharmacological and non-pharmacological treatments.
• Pregnancy Sickness Support: UK charity providing support, information, and advocacy. Healthcare professional resources and clinical updates available at pregnancysicknesssupport.org.uk.
• Hyperemesis Education and Research (HER) Foundation: International resource with research updates, clinical tools, and patient support materials. Available at hyperemesis.org.
• ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. American guidance that may be useful for comparison, particularly regarding doxylamine-pyridoxine combination therapy.

What Patients Wish Their Healthcare Providers Understood

The following themes emerge consistently from patient experience surveys, helpline contacts, and research conducted by Pregnancy Sickness Support. This feedback is shared constructively to improve care:

"It is not just morning sickness"

The term "morning sickness" minimises the experience. Many women with moderate NVP and virtually all women with HG are ill throughout the day and night, for weeks or months. The condition can be completely incapacitating. Comparing HG to "normal morning sickness" is experienced as dismissive and hurtful. Use the clinical terms: nausea and vomiting of pregnancy, or hyperemesis gravidarum.

"Being told to eat ginger biscuits when I cannot keep water down is demoralising"

While ginger has some evidence for mild nausea, offering it as a treatment for moderate or severe NVP is perceived as not taking the condition seriously. If a woman has presented to healthcare because of her symptoms, she has almost certainly already tried all the home remedies. Move directly to pharmacological treatment.

"I needed someone to believe how ill I was"

Validation is therapeutic. Many women describe feeling disbelieved, dismissed, or told that their symptoms are "normal" or "will pass." Simply acknowledging the severity of their condition and stating that treatment is available can have an enormous impact on a woman's ability to cope. Use phrases such as: "This sounds very difficult. Let's get you some treatment."

"I was terrified of taking medication but more terrified of how I felt"

Women are acutely aware of the responsibility of taking medication in pregnancy. Many will refuse treatment or delay seeking help because of fear. Providing clear, evidence-based reassurance about medication safety is part of your clinical duty. Print or direct women to the UKTIS/Bumps leaflets for additional written reassurance.

"The mental health impact lasted long after the sickness stopped"

PTSD, depression, anxiety, and bonding difficulties can persist well beyond the resolution of physical symptoms. Some women describe the psychological aftermath as worse than the condition itself. Ask about mental health at postnatal checks, not just during pregnancy. Offer referrals proactively.

"I should not have had to fight for treatment"

Multiple women report attending GP surgeries and A&E departments multiple times before receiving appropriate treatment. Some are sent home with only paracetamol. Others are told to "try again tomorrow" while visibly dehydrated. Every presentation should be taken seriously. Every woman deserves prompt, proactive treatment without having to advocate for herself while acutely unwell.